---
title: "Satellos Q2 2026 loss widens as R&D spending rises on SAT-3247 BASECAMP, TRAILHEAD trials, company says"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295849207.md"
description: "Satellos Bioscience reported a widened net loss of USD 11.72 million in Q2 2026, up from USD 5.61 million, driven by increased R&D spending on SAT-3247 trials (BASECAMP and TRAILHEAD). R&D expenses rose to USD 9.64 million due to clinical activity, manufacturing work, and preclinical studies. General and administrative expenses also increased to USD 2.53 million. Cash and short-term investments reached USD 61.84 million at June 30, 2026, bolstered by USD 51.9 million in net offering proceeds."
datetime: "2026-08-13T21:21:16.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295849207.md)
  - [en](https://longbridge.com/en/news/295849207.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295849207.md)
generator: "portal-rs"
---

# Satellos Q2 2026 loss widens as R&D spending rises on SAT-3247 BASECAMP, TRAILHEAD trials, company says

-   Satellos posted a net loss of USD 11.72 million in Q2 2026, widened from USD 5.61 million as spending rose. \* R&D expense climbed to USD 9.64 million from USD 4.44 million, driven by BASECAMP and TRAILHEAD clinical activity. \* Higher manufacturing work and preclinical safety studies also lifted R&D costs, alongside increased headcount supporting expanded development. \* G&A expense increased to USD 2.53 million from USD 1.93 million, reflecting higher professional fees and operating costs tied to Nasdaq reporting. \* Cash and short-term investments totaled USD 61.84 million at June 30, 2026, up from USD 27.71 million following USD 51.9 million net offering proceeds. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Satellos Bioscience Inc. published the original content used to generate this news brief on August 13, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [MSLE.US](https://longbridge.com/en/quote/MSLE.US.md)

## Related News & Research

- [Satellos Bioscience posts investor deck outlining SAT-3247 muscle-regeneration approach for Duchenne dystrophy](https://longbridge.com/en/news/296435378.md)
- [APA Corp announces Q3 2026 distribution of R$ 0.87 per unit](https://longbridge.com/en/news/297039472.md)
- [IBA publishes H1 2026 results presentation](https://longbridge.com/en/news/297180350.md)
- [Exmar announces availability of 2026 half-year results release](https://longbridge.com/en/news/296992548.md)
- [Petrolia Noco announces availability of Q2 2026 report](https://longbridge.com/en/news/296871879.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**